This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
What's in Store for Edwards Lifesciences' (EW) Q3 Earnings?
by Zacks Equity Research
Robust customer adoption of the TruWave disposable pressure monitoring devices and the INSPIRIS RESILIA aortic valve is likely to have driven Edwards Lifesciences' (EW) Q3 revenues.
Why Abbott (ABT) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Abbott (ABT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
The Zacks Analyst Blog Highlights: Visa, Walmart, Abbott Laboratories, UnitedHealth Group and Oracle
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Visa, Walmart, Abbott Laboratories, UnitedHealth Group and Oracle
Abbott's New Antibody Test Gets FDA's EUA, Test Suite Expands
by Zacks Equity Research
Abbott's (ABT) latest antibody test is expected to give a clearer picture of the rate of recovery post coronavirus infection.
Here's Why Momentum Investors Will Love Abbott (ABT)
by Zacks Equity Research
Does Abbott (ABT) have what it takes to be a top stock pick for momentum investors? Let's find out.
Abbott (ABT) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Abbott (ABT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Is Abbott Laboratories (ABT) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (ABT) Outperforming Other Medical Stocks This Year?
Abbott's Data From Interim Clinical Study of ID NOW Positive
by Zacks Equity Research
Abbott's (ABT) recent data from an interim clinical study on its ID NOW COVID-19 rapid test reflects the test's capacity to deliver effective, consistent and reliable performance.
Top Research Reports for Visa, Walmart & Abbott
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Visa (V), Walmart (WMT) and Abbott Laboratories (ABT).
3 Large-Cap MedTech Growth Stocks to Buy Amid the Pandemic
by Sriparna Ghosal
Let's take a look at three large-cap MedTech stocks that are currently flourishing on the back of a number of positive developments.
Coronavirus Drives Testing Stocks: Is There Room for More Upside?
by Urmimala Biswas
Given the current testing requirements across the world, the diagnostic testing business for COVID-19 is rapidly evolving.
Abbott (ABT) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed the most recent trading day at $108.56, moving +1.93% from the previous trading session.
Masimo's (MASI) Rad-G Pulse Oximeter Receives FDA Clearance
by Zacks Equity Research
Masimo's (MASI) Rad-G Pulse Oximeter receives FDA clearance, thereby allowing clinicians to access the most accurate and reliable pulse oximetry monitoring technologies.
Abbott's Libre 3 Receives CE Mark, Boosts CGM Prospects
by Zacks Equity Research
Abbott's (ABT) environment-friendly next-generation FreeStyle Libre 3 system aims to provide a better quality of life to diabetics in Europe at the same affordable price of previous systems.
3 Beaten-Down MedTech Stocks to Grab Amid Market Meltdown
by Sriparna Ghosal
These cheap MedTech stocks are currently flourishing on the back of a number of positive developments.
Abbott (ABT) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed at $105.19 in the latest trading session, marking a +0.72% move from the prior day.
3 Great MedTech Stocks to Pick Amid the Coronavirus Crisis
by Sriparna Ghosal
Backed by projections of robust earnings growth rates, there are a few MedTech stocks which are ideal for long-term bet.
Abbott's MitraClip G4 Receives CE Mark for Treatment of MR
by Zacks Equity Research
Abbott's (ABT) MitraClip G4 is expected to improve MR patients' quality of life post its usage eligibility in Europe and other countries recognizing the CE Mark.
Abbott (ABT) Stock Moves -1.98%: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed the most recent trading day at $102.73, moving -1.98% from the previous trading session.
4 Best Diabetes Device Stocks to Focus on Amid Coronavirus Crisis
by Debanjana Dey
Here are a few diabetes-centric MedTech stocks that investors can focus on to reap profits amid the pandemic-battered stock market situation.
Abbott Launches Sports Biosensor in Europe, Boosts CGM Wing
by Zacks Equity Research
Abbott (ABT) makes its first non-exclusive collaboration with Atlanta-based sports technology company, Supersapiens.
Abbott (ABT) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed at $106.66 in the latest trading session, marking a +0.91% move from the prior day.
The Zacks Analyst Blog Highlights: Quest Diagnostics, Abbott, Quidel, QIAGEN and Thermo Fisher Scientific
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Quest Diagnostics, Abbott, Quidel, QIAGEN and Thermo Fisher Scientific
Abbott (ABT) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed at $104.70 in the latest trading session, marking a +0.67% move from the prior day.
Coronavirus Test Makers With Scope to Maximize Investor Benefits
by Urmimala Biswas
The surge in new coronavirus infections broadens the scope for antigen and antibody tests.